Key facts
- This page summarizes Ross Moat's Form 4 filing for Kiniksa Pharmaceuticals, Ltd. (KNSA).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 11 Apr 2022, 16:30.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Award
Award
Additional SEC filing notes
Footnote F1
The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 7, 2022.
Footnote F2
Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.
Footnote F3
The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022.